[1]
|
Annonymous (2017) United Nations World Population Ageing—Highlights. https://www.un.org/en/development/desa/population/publications/pdf/ageing/ WPA2017_Highlights.pdf
|
[2]
|
Bergman, H., et al. (2013) Understanding and Meeting the Needs of the Older Population: A Global Challenge. Canadian Geriatrics Journal, 16, 61-65. https://cgjonline.ca/index.php/cgj/article/view/60 https://doi.org/10.5770/cgj.16.60
|
[3]
|
Chang, A.Y., Skirbekk, V.F., Tyrovolas, S., Kassebaum, N.J. and Dieleman, J.L. (2019) Measuring Population Ageing: An Analysis of the Global Burden of Disease Study 2017. The Lancet Public Health, 4, e159-e167. https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(19)30019-2/fulltext https://doi.org/10.1016/S2468-2667(19)30019-2
|
[4]
|
Boss, G.R. and Seegmiller, J.E. (1981) Age-Related Physiological Changes and Their Clinical Significance. Western Journal of Medicine, 135, 434-440. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1273316/pdf/westjmed00220-0011.pdf
|
[5]
|
McLean, A.J. and Le Couteur, D.G. (2004) Aging Biology and Geriatric Clinical Pharmacology. Pharmacological Reviews, 56, 163-184. http://pharmrev.aspetjournals.org/content/56/2/163.long https://doi.org/10.1124/pr.56.2.4
|
[6]
|
Schmucker, D.L. (1985) Aging and Drug Disposition: An Update. Pharmacological Reviews, 37, 133-148. http://pharmrev.aspetjournals.org/content/37/2/133.long https://doi.org/10.1080/03085698508592599
|
[7]
|
Woodhouse, K. (1992) Drugs and the Liver. Part III: Ageing of the Liver and the Metabolism of Drugs. Biopharmaceutics & Drug Disposition, 13, 311-320. https://www.ncbi.nlm.nih.gov/pubmed/1498264 https://doi.org/10.1002/bdd.2510130502
|
[8]
|
Linjakumpu, T., et al. (2002) Use of Medications and Polypharmacy Are Increasing among the Elderly. Journal of Clinical Epidemiology, 55, 809-817. https://www.jclinepi.com/article/S0895-4356(02)00411-0/fulltext https://doi.org/10.1016/S0895-4356(02)00411-0
|
[9]
|
Quinn, K.J. and Shah, N.H. (2017) A Dataset Quantifying Polypharmacy in the United States. Scientific Data, 4, Article No. 170167. https://www.nature.com/articles/sdata2017167 https://doi.org/10.1038/sdata.2017.167
|
[10]
|
Morin, L., Johnell, K., Laroche, M.L., Fastbom, J. and Wastesson, J.W. (2018) The Epidemiology of Polypharmacy in Older Adults: Register-Based Prospective Cohort Study. Clinical Epidemiology, 10, 289-298. https://www.dovepress.com/the-epidemiology-of-polypharmacy-in-older-adults-register-based-prospe-peer-reviewed-article-CLEP https://doi.org/10.2147/CLEP.S153458
|
[11]
|
Dagli, R.J. and Sharma, A. (2014) Polypharmacy: A Global Risk Factor for Elderly People. Journal of International Oral Health, 6, 1-2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295469/pdf/JIOH-6-i.pdf
|
[12]
|
Maher, R.L., Hanlon, J. and Hajjar, E.R. (2014) Clinical Consequences of Polypharmacy in Elderly. Expert Opinion on Drug Safety, 13, 57-65. https://www.tandfonline.com/doi/abs/10.1517/14740338.2013.827660?journalCode=ieds20 https://doi.org/10.1517/14740338.2013.827660
|
[13]
|
Khandeparkar, A. and Rataboli, P.V. (2017) A Study of Harmful Drug-Drug Interactions Due to Polypharmacy in Hospitalized Patients in Goa Medical College. Perspectives in Clinical Research, 8, 180-186. http://www.picronline.org/temp/PerspectClinRes84180-4080127_112001.pdf https://doi.org/10.4103/picr.PICR_132_16
|
[14]
|
Ogu, C.C. and Maxa, J.L. (2000) Drug Interactions Due to Cytochrome P450. Proceedings (Baylor University. Medical Center), 13, 421-423. https://www.tandfonline.com/doi/pdf/10.1080/08998280.2000.11927719?needAccess=true https://doi.org/10.1080/08998280.2000.11927719
|
[15]
|
Zanger, U.M. and Schwab, M. (2013) Cytochrome P450 Enzymes in Drug Metabolism: Regulation of Gene Expression, Enzyme Activities, and Impact of Genetic Variation. Pharmacology & Therapeutics, 138, 103-141. https://www.sciencedirect.com/science/article/pii/S0163725813000065?via%3Dihub https://doi.org/10.1016/j.pharmthera.2012.12.007
|
[16]
|
Estabrook, R.W. (2003) A Passion for P450s (Rememberances of the Early History of Research on Cytochrome P450). Drug Metabolism & Disposition, 31, 1461-1473. http://dmd.aspetjournals.org/content/31/12/1461 https://doi.org/10.1124/dmd.31.12.1461
|
[17]
|
McDonnell, A.M. and Dang, C.H. (2013) Basic Review of the Cytochrome p450 System. Journal of the Advanced Practitioner in Oncology, 4, 263-268. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093435 https://doi.org/10.6004/jadpro.2013.4.4.7
|
[18]
|
Klingenberg, M. (1958) Pigments of Rat Liver Microsomes. Archives of Biochemistry and Biophysics, 75, 376-386. https://www.sciencedirect.com/science/article/abs/pii/0003986158904363?via%3Dihub https://doi.org/10.1016/0003-9861(58)90436-3
|
[19]
|
Cooper, D.Y., Levin, S., Narasimhulu, S. and Rosenthal, O. (1965) Photochemical Action Spectrum of the Terminal Oxidase of Mixed Function Oxidase Systems. Science, 147, 400-402. https://science.sciencemag.org/content/147/3656/400.long https://doi.org/10.1126/science.147.3656.400
|
[20]
|
Bull, J.A., Croft, R.A., Davis, O.A., Doran, R. and Morgan, K.F. (2016) Oxetanes: Recent Advances in Synthesis, Reactivity, and Medicinal Chemistry. Chemical Reviews, 116, 12150-12233. https://doi.org/10.1021/acs.chemrev.6b00274 https://pubs.acs.org/doi/pdf/10.1021/acs.chemrev.6b00274?rand=pf5dnqxs
|
[21]
|
Carreira, E.M. and Fessard, T.C. (2014) Four-Membered Ring-Containing Spirocycles: Synthetic Strategies and Opportunities. Chemical Reviews, 114, 8257-8322. https://pubs.acs.org/doi/10.1021/cr500127b https://doi.org/10.1021/cr500127b
|
[22]
|
Wuitschik, G., et al. (2010) Oxetanes in Drug Discovery: Structural and Synthetic Insights. Journal of Medicinal Chemistry, 53, 3227-3246. https://pubs.acs.org/doi/abs/10.1021/jm9018788 https://doi.org/10.1021/jm9018788
|
[23]
|
Magnin, D.R., et al. (2004) Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability: Interplay between the N-Terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of Alpha-Aminoacyl-l-cis-4,5-Methanoprolinenitrile-Based Inhibitors. Journal of Medicinal Chemistry, 47, 2587-2598. https://pubs.acs.org/doi/10.1021/jm049924d https://doi.org/10.1021/jm049924d
|
[24]
|
von Rauch, M., Schlenk, M. and Gust, R. (2004) Effects of C2-alkylation, N-alkylation, and N,N’-dialkylation on the Stability and Estrogen Receptor Interaction of (4R,5S)/(4S,5R)-4,5-bis(4-hydroxyphenyl)-2-imidazolines. Journal of Medicinal Chemistry, 47, 915-927. https://pubs.acs.org/doi/10.1021/jm0309809 https://doi.org/10.1021/jm0309809
|
[25]
|
Manoury, P.M., Binet, J.L., Rousseau, J., Lefevre-Borg, F. and Cavero, I.G. (1987) Synthesis of a Series of Compounds Related to Betaxolol, a New Beta 1-Adrenoceptor Antagonist with a Pharmacological and Pharmacokinetic Profile Optimized for the Treatment of Chronic Cardiovascular Diseases. Journal of Medicinal Chemistry, 30, 1003-1011. https://www.ncbi.nlm.nih.gov/pubmed/2884312 https://doi.org/10.1021/jm00389a008
|
[26]
|
Borthwick, A.D., et al. (2003) Design and Synthesis of Pyrrolidine-5,5’-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as Novel Mechanism-Based Inhibitors of Human Cytomegalovirus Protease. 4. Antiviral Activity and Plasma Stability. Journal of Medicinal Chemistry, 46, 4428-4449. https://pubs.acs.org/doi/abs/10.1021/jm030810w https://doi.org/10.1021/jm030810w
|
[27]
|
Madsen, P., et al. (2002) Optimization of Alkylidene Hydrazide Based Human Glucagon Receptor Antagonists. Discovery of the Highly Potent and Orally Available 3-Cyano-4-Hydroxybenzoic Acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylme-thylene]hydrazide. Journal of Medicinal Chemistry, 45, 5755-5775. https://pubs.acs.org/doi/10.1021/jm0208572 https://doi.org/10.1021/jm0208572
|
[28]
|
Duffy, J.L., et al. (2003) HIV Protease Inhibitors with Picomolar Potency against PI-Resistant HIV-1 by Extension of the P3 Substituent. Bioorganic & Medicinal Chemistry Letters, 13, 2569-2572. https://doi.org/10.1016/S0960-894X(03)00475-X https://www.sciencedirect.com/science/article/pii/S0960894X0300475X?via%3Dihub
|
[29]
|
Ahmad, S., et al. (2001) Arylcyclopropanecarboxyl Guanidines as Novel, Potent, and Selective Inhibitors of the Sodium Hydrogen Exchanger Isoform-1. Journal of Medicinal Chemistry, 44, 3302-3310. https://pubs.acs.org/doi/10.1021/jm010100v https://doi.org/10.1021/jm010100v
|
[30]
|
Toselli, F., et al. (2019) Hip to Be Square: Oxetanes as Design Elements to Alter Metabolic Pathways. Journal of Medicinal Chemistry, 62, 7383-7399. https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00030 https://doi.org/10.1021/acs.jmedchem.9b00030
|
[31]
|
Stepan, A.F., et al. (2011) Metabolism-Directed Design of Oxetane-Containing Arylsulfonamide Derivatives as Gamma-Secretase Inhibitors. Journal of Medicinal Chemistry, 54, 7772-7783. https://pubs.acs.org/doi/10.1021/jm200893p https://doi.org/10.1021/jm200893p
|
[32]
|
Lu, H., et al. (2018) Discovery of Novel 1-Cyclopentenyl-3-Phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists. Journal of Medicinal Chemistry, 61, 2518-2532. https://doi.org/10.1021/acs.jmedchem.7b01854 https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.7b01854
|
[33]
|
Crawford, J.J., et al. (2018) Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development. Journal of Medicinal Chemistry, 61, 2227-2245. https://doi.org/10.1021/acs.jmedchem.7b01712 https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01712
|
[34]
|
Ouvry, G., et al. (2018) Discovery and Characterization of CD12681, a Potent RORgamma Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis. ChemMedChem, 13, 321-337. https://doi.org/10.1002/cmdc.201700758 https://onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.201700758
|
[35]
|
Cheong, J.E., et al. (2018) Synthesis and Anticancer Activity of Novel Water Soluble Benzimidazole Carbamates. European Journal of Medicinal Chemistry, 144, 372-385. https://doi.org/10.1016/j.ejmech.2017.11.037 https://www.sciencedirect.com/science/article/pii/S0223523417309406?via%3Dihub
|
[36]
|
Geary, G.C., et al. (2018) Densely Functionalised Spirocyclic Oxetane-Piperidine Scaffolds for Drug Discovery. Bioorganic & Medicinal Chemistry, 26, 791-797. https://pubs.acs.org/doi/full/10.1021/jm9018788?src=recsys https://doi.org/10.1016/j.bmc.2017.12.012
|
[37]
|
Bezencon, O., et al. (2017) Discovery of a Potent, Selective T-Type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies. Journal of Medicinal Chemistry, 60, 9769-9789. https://doi.org/10.1021/acs.jmedchem.7b01236 https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01236
|
[38]
|
Li, X.Q., et al. (2016) Discovery of a Novel Microsomal Epoxide Hydrolase-Cata-lyzed Hydration of a Spiro Oxetane. Drug Metabolism & Disposition, 44, 1341-1348. http://dmd.aspetjournals.org/content/dmd/44/8/1341.full.pdf https://doi.org/10.1124/dmd.116.071142
|
[39]
|
Morisseau, C. and Hammock, B.D. (2005) Epoxide Hydrolases: Mechanisms, Inhibitor Designs, and Biological Roles. Annual Review of Pharmacology and Toxicology, 45, 311-333. https://doi.org/10.1146/annurev.pharmtox.45.120403.095920 https://www.annualreviews.org/doi/abs/10.1146/annurev.pharmtox.45.120403.095920?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=pharmtox
|
[40]
|
Vaclavikova, R., Hughes, D.J. and Soucek, P. (2015) Microsomal Epoxide Hydrolase 1 (EPHX1): Gene, Structure, Function, and Role in Human Disease. Gene, 571, 1-8. https://www.sciencedirect.com/science/article/abs/pii/S0378111915009129?via%3Dihub https://doi.org/10.1016/j.gene.2015.07.071
|
[41]
|
Toselli, F., et al. (2017) Oxetane Substrates of Human Microsomal Epoxide Hydrolase. Drug Metabolism & Disposition, 45, 966-973. http://dmd.aspetjournals.org/content/dmd/45/8/966.full.pdf https://doi.org/10.1124/dmd.117.076489
|
[42]
|
Hutzler, J.M., Obach, R.S., Dalvie, D. and Zientek, M.A. (2013) Strategies for a Comprehensive Understanding of Metabolism by Aldehyde Oxidase. Expert Opinion on Drug Metabolism & Toxicology, 9, 153-168. https://www.tandfonline.com/doi/abs/10.1517/17425255.2013.738668?journalCode=iemt20 https://doi.org/10.1517/17425255.2013.738668
|
[43]
|
Foti, R.S. and Dalvie, D.K. (2016) Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics. Drug Metabolism & Disposition, 44, 1229-1245. http://dmd.aspetjournals.org/content/dmd/44/8/1229.full.pdf https://doi.org/10.1124/dmd.116.071753
|
[44]
|
Argikar, U.A., Potter, P.M., Hutzler, J.M. and Marathe, P.H. (2016) Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance. The AAPS Journal, 18, 1391-1405. https://link.springer.com/article/10.1208%2Fs12248-016-9962-6 https://doi.org/10.1208/s12248-016-9962-6
|
[45]
|
Jensen, K.G., et al. (2017) Lack of Exposure in a First-in-Man Study Due to Aldehyde Oxidase Metabolism: Investigated by Use of 14C-microdose, Humanized Mice, Monkey Pharmacokinetics, and in Vitro Methods. Drug Metabolism & Disposition, 45, 68-75. http://dmd.aspetjournals.org/content/dmd/45/1/68.full.pdf https://doi.org/10.1124/dmd.116.072793
|